How to Choose a Patient Support Program Partner in Egypt: A Checklist for Pharma Teams
Quick answer
A practical checklist for pharma and market-access teams: eight criteria, twelve questions, red flags and a short pilot to compare patient support program partners in Egypt.
Short answer: choose a patient support program partner by scoring it on eight things: clinical staffing, contact cadence, services beyond education, caregiver involvement, reporting, safety and privacy handling, handover to the care team, and field reach in Egypt. Then run a short pilot with agreed measures before scaling. This guide is operational, not legal or medical advice.
- A July 2026 Pharmaceutical Commerce analysis (authors from Coforge) reports that programmes using registered nurses or pharmacists as the main contact outperformed those relying on untrained customer-service staff, citing Tan et al. (2010), and that education alone, especially written material without reinforcement, shows limited impact.
- The same article suggests weekly to biweekly contact at initiation and monthly to quarterly after that, and says involving family or caregivers improves outcomes. These are the authors' recommendations, not Egyptian regulatory requirements.
- It also lists the usual criticisms: manufacturer conflicts of interest, fragmented enrolment, opacity, non-standardised success metrics and, for outsourced hubs, risks around brand control, data access and consistency of patient experience. A good partner selection process tests for each of these.
- Egypt adds practical tests: Arabic-language delivery, home-visit reach beyond Cairo, and a clean handover to the treating team. Public programmes are moving the same way: Egypt's Healthcare Authority launched a winter home-visit drive for more than 7,000 chronic, elderly and disabled patients in UHIS governorates in December 2025.
- Do not choose on the brochure. Score partners on the same sheet, then run a time-boxed pilot with KPIs agreed in advance.
Why the choice of partner matters more than the proposal
Most vendor proposals look alike: an enrolment hub, nurse educators, reminders, a dashboard. The differences that decide whether a programme works are operational: who actually speaks to the patient, how often, what happens when the patient does not answer, and what the sponsor can see afterwards. The Pharmaceutical Commerce authors make the same point from the other side: manufacturers rarely disclose utilisation, costs or outcomes, and success metrics are not standardised. In Egypt, where many programmes start as a launch commitment for a specialty or biologic therapy, the sponsor often has to define those measures before the first patient is enrolled.
Eight criteria to score every partner on
| Criterion | What to test | Why it matters |
|---|---|---|
| 1. Clinical staffing | Who is the first contact: a nurse or pharmacist, or a call-centre agent? What training and supervision do they have? | The Pharmaceutical Commerce article cites evidence that clinician-led contact outperforms untrained customer service. |
| 2. Contact cadence | How often is each patient contacted in months 1 to 3 and 4 to 12? What is the rule when a call is missed? | The article suggests weekly to biweekly at initiation, then monthly to quarterly. |
| 3. More than education | Does the service include coordination, follow-up on prescriptions and practical help, or leaflets only? | Education alone, especially written material, shows limited impact. |
| 4. Caregiver involvement | Can a family member be included, with consent? In Arabic? | Caregiver involvement is linked to better outcomes in the same article. |
| 5. Reporting | What do you see weekly and monthly, and can you audit it? Are definitions written down? | Cencora's published questions stress tools for monitoring programme performance and staffing. See our guide to PSP KPIs. |
| 6. Safety and privacy | How are adverse events captured and passed on, and how is patient consent recorded? | These are sponsor responsibilities even when delivery is outsourced. See our guides on adverse event reporting and consent and privacy. |
| 7. Handover | What is the agreed route from referral to the treating team, and back? Who owns the next step? | Gaps at handover are where patients are lost. See our guide to PSP referral handover. |
| 8. Egypt field reach | Which governorates can the partner visit, in what language, with which clinical staff? | Coverage claims should be confirmed in writing, not assumed from a Cairo office. |
Twelve questions to ask in the first meeting
Cencora, a PSP vendor, publishes five questions for sponsors choosing a partner: how automation is used, what access challenges patients will face, what tools exist to manage the programme, how those tools compare with competitors, and how the voice of the customer shapes the service. Treat them as vendor-authored, and add the questions that matter locally:
- Who will speak to my patients, and what is their clinical background?
- What is the contact schedule in the first 90 days, and what happens after two missed contacts?
- Which activities are clinical, which are administrative, and who is accountable for each?
- What access barriers do you expect for this therapy in Egypt, and what can the programme actually do about them?
- What data will we receive, how often, in what format, and who owns it?
- How are adverse events and product complaints captured, timed and escalated to us?
- How is patient consent recorded, and how can a patient withdraw?
- How do you hand patients to, and receive them from, the treating physician or hospital?
- Which governorates can you serve with your own staff, and which through subcontractors?
- What would you change after the first eight weeks if the numbers disappoint?
- What does the partner do to avoid influencing prescribing decisions?
- What is not included in the price?
Red flags in a proposal
- Outcome or adherence guarantees. No honest partner can promise a percentage before seeing the therapy, the patients and the access pathway.
- No named clinical lead, or nurses who are 'available' but not employed or supervised by the partner.
- A dashboard that shows activity (calls made) but not what happened to the patient.
- Coverage described as 'nationwide' with no list of governorates, staff or response times.
- Vague answers on consent, adverse events or data ownership.
- A price that cannot be tied to defined activities. For how costs are usually structured, read our PSP cost guide.
A realistic scenario: a launch team in Cairo
Consider an illustrative example, not a Hospitalia client case. A multinational's Egypt medical team is preparing to launch a self-injected biologic. Three partners present similar decks. The team sends all three the same scoring sheet and the twelve questions above. Partner A answers every question in writing but staffs the first contact with agents rather than nurses. Partner B has nurses but cannot list the governorates it can visit. Partner C is stronger on handover and consent but weaker on reporting. Instead of choosing a winner on the slides, the team runs an eight-week pilot with Partner B and Partner C on a small patient cohort, with agreed measures: enrolment completed, first contact within the agreed window, contacts achieved against plan, adverse events forwarded on time, and patient and physician feedback. The pilot's numbers, not the brochures, decide the contract.
A note on bias, including ours
Hospitalia provides patient support services, so you should apply this checklist to us as well. Our stated scope is onboarding, patient education, follow-up and care coordination, with home visits where they are clinically appropriate. Scope, coverage, staffing, timelines and commercial terms are defined in a scoping conversation, not assumed from a web page, and we do not offer outcome guarantees.
How Hospitalia can help
If you are scoping a programme, we can walk through this checklist with your medical and market-access team, define the activities and measures in writing, and agree a pilot. See also our guides on whether to build or outsource a PSP and how to join a patient support program in Egypt.
Call 01063151838 or send us a short brief and we will respond with the questions we would ask you.
Discuss your programmeFrequently asked questions
What should a pharma company ask a patient support program provider?
Ask who the first patient contact is and how they are trained, the contact schedule in the first 90 days, what data and reports you receive, how adverse events and consent are handled, how patients are handed to the treating team, and which Egyptian governorates the provider can serve with its own staff.
Should patient support nurses be employed by the pharma company or the partner?
Both models exist. The Pharmaceutical Commerce article notes that manufacturer-sponsored clinicians may face conflict-of-interest criticism, while outsourcing raises questions about brand control, data access and consistency. Whichever you choose, define accountability and supervision in writing.
How often should a PSP contact patients?
The Pharmaceutical Commerce authors suggest weekly to biweekly contact at initiation, then monthly to quarterly, and link regular contact in the first 12 months to better adherence and persistence. The right schedule for your therapy is a clinical and operational decision.
How long should a pilot run before scaling?
There is no standard. One practical option is a short, time-boxed pilot, such as eight weeks, with measures agreed in advance, extended only if the numbers and the patient and physician feedback justify it. This is a practical suggestion, not a regulatory rule.
Which KPIs should I use to compare PSP partners?
Use activity and outcome-process measures you can define precisely, such as enrolment completed, time to first contact, contacts achieved against plan, adverse events forwarded on time and feedback. Avoid promising adherence percentages up front. See our guide to PSP KPIs in Egypt.
How is a PSP priced in Egypt?
Pricing usually follows the activities and staffing you define, so ask for a price tied to a written scope and list what is excluded. Our PSP cost guide explains the common structures without quoting prices.
